Comparison · NCT02181075-2f4697b9
Part I (Patients Enrolled Between March 2015-April 2017) vs Part II (Patients Enrolled Between June 2016-Feb 2017): Patients With Significant (Grade 3-5) Adverse Event(s) Deemed Related to ThermoDox (LTLD)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Part I (Patients Enrolled Between March 2015-April 2017) vs Part II (Patients Enrolled Between June 2016-Feb 2017): Patients With Significant (Grade 3-5) Adverse Event(s) Deemed Related to ThermoDox (LTLD). Trial comparisons, record NCT02181075-2f4697b9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02181075-2f4697b9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.5 | 0.188 | 0.812 | wilson | |
| Risk in group 2 | 1 | 0.51 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | -0.5 | -0.812 | 0.081 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.5 | 0.225 | 1.11 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Part I (Patients Enrolled Between March 2015-April 2017) than on Part II (Patients Enrolled Between June 2016-Feb 2017) | 2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Part I (Patients Enrolled Between March 2015-April 2017) | Arm 1 - see above | 3 | 6 | OG000 |
| Group 2 | Part II (Patients Enrolled Between June 2016-Feb 2017) | Arm 2 - see above | 4 | 4 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Patients With Significant (Grade 3-5) Adverse Event(s) Deemed Related to ThermoDox (LTLD)
- Description
Adverse Events are listed separately in the subsequent results, but were also specified as a secondary endpoint in the a priori protocol and thus significant events are summarised here.~'Definitely' or 'Probably' related events are included.
- Time frame
- Up to 30 days post-intervention (Day 1-30)
- Population
Source ClinicalTrials.gov
Trial
- Title
- Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours
- NCT number
- NCT02181075
- Phases
- PHASE1
- Conditions
- Liver Tumour
- Interventions
ThermoDox® (LTLD), Focused Ultrasound of Target Liver Tumour, Pre-LTLD Biopsy of Target Liver Tumour, Post-LTLD Biopsy of Target Liver Tumour, Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour, Thermometry of Target Tumour
- Lead sponsor
- University of Oxford
- Results first posted
- 2019-06-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02181075?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02181075-2f4697b9